SEC 13F Intelligence

Payden & Rygel / ABBV

Payden & Rygel’s Abbvie Inc Position

Does Payden & Rygel own Abbvie Inc (ABBV)? Yes — 72.7K shares worth $16M (+1.22% of its 13F portfolio) as of Q1 2026, up from 57.0K shares the prior filed quarter.

Position Value
$16M
Q1 2026
Shares
72.7K
% of Portfolio
+1.22%
Quarters Held
26
currently held

Position History ABBV

Reported value by quarter
Q1 ’19: $822,000Q1 ’19Q2 ’19: $742,000Q3 ’19: $772,000Q4 ’19: $17MQ1 ’20: $16MQ1 ’20Q2 ’20: $20MQ3 ’20: $19MQ4 ’20: $23MQ1 ’21: $24MQ1 ’21Q2 ’21: $22MQ3 ’21: $30MQ4 ’21: $47MQ1 ’22: $35MQ1 ’22Q2 ’22: $38MQ3 ’22: $34MQ4 ’22: $34MQ1 ’23: $24MQ1 ’23Q2 ’23: $17MQ4 ’23: $776,000Q3 ’24: $989,000Q4 ’24: $20,000Q4 ’24Q1 ’25: $11MQ2 ’25: $20,000Q3 ’25: $13MQ4 ’25: $13MQ4 ’25Q1 ’26: $16Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202672.7K$16M+1.22%
Q4 202557.0K$13M+0.90%
Q3 202557.4K$13M+1.10%
Q2 2025110$20,0000.00%
Q1 202551.0K$11M+0.92%
Q4 2024110$20,0000.00%
Q3 20245.0K$989,000+0.08%
Q4 20235.0K$776,000+0.05%
Q2 2023122.7K$17M+1.17%
Q1 2023148.3K$24M+1.40%
Q4 2022208.3K$34M+1.79%
Q3 2022251.1K$34M+1.97%
Q2 2022246.6K$38M+2.27%
Q1 2022212.9K$35M+1.74%
Q4 2021350.4K$47M+2.19%
Q3 2021280.9K$30M+1.57%
Q2 2021191.8K$22M+1.03%
Q1 2021225.2K$24M+1.13%
Q4 2020212.2K$23M+1.17%
Q3 2020215.6K$19M+1.12%
Q2 2020208.5K$20M+1.30%
Q1 2020208.5K$16M+1.15%
Q4 2019192.8K$17M+1.07%
Q3 201910.2K$772,000+0.05%
Q2 201910.2K$742,000+0.05%
Q1 201910.2K$822,000+0.06%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Payden & Rygel’s full portfolio or all institutional holders of ABBV.